Therapeutic Strategy Details
| Strategy ID: | S11 |
| Strategy: | Anti-hypertensive |
| Other Terms: | None |
| Related Targets: | angiotensin converting enzyme inhibitors (ACEi) ; angiotensin II receptor blockers (ARBs) |
| Related Drugs: | Captopril |
| Mechanism: | The renin-angiotensin system is involved in hepatic fibrosis through activation of hepatic stellate cells, major fibrogenic cells in the liver. Hepatic stellate cells are activated by liver injury to express excessive matrix proteins and profibrogenic cytokines such as transforming growth factor-beta 1. There is a significant relationship between inheritance of high transforming growth factor (TGF)-beta1 and angiotensinogen-producing genotypes and the development of progressive hepatic fibrosis in patients with chronic hepatitis C. |
| Reference (PMIDs): | 15382153; 17518368; 11438504 |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D232 | Moxonidine | Chemical drug | DB09242 | NISCH agonist | -- | Under clinical trials | Details |
| D267 | Perindopril | Chemical drug | DB00790 | ACE inhibitor | Antihypertensive drug | Under clinical trials | Details |
| D344 | Spironolactone | Chemical drug | DB00421 | AR antagonist; PGR agonist; NR1I2 | Diuretic drug | Under clinical trials | Details |
| D360 | Telmisartan | Chemical drug | DB00966 | PPARG partial agonist | Improve insulin resistance | Under clinical trials | Details |
| D480 | Guanabenz | Chemical drug | DB00629 | -- | -- | Under clinical trials | Details |
| D541 | Olmesartan | Chemical drug | DB00275 | -- | -- | Under clinical trials | Details |
| D586 | CGS21680 | Miscellany | -- | Adenosine A2 receptor agonists | Antiepileptic drugs; Antihypertensives; Antiparkinsonians; Anxiolytics; Neuroprotectants | Under investigation | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0064 | DB00177 | approved; investigational | small molecule | Valsartan | Therapeutic strategy associated | Details |
| R0065 | DB00178 | approved | small molecule | Ramipril | Therapeutic strategy associated | Details |
| R0075 | DB00203 | approved; investigational | small molecule | Sildenafil | Indication associated | Details |
| R0077 | DB00206 | approved; investigational | small molecule | Reserpine | Therapeutic strategy associated | Details |
| R0081 | DB00214 | approved | small molecule | Torasemide | Therapeutic strategy associated | Details |
| R0084 | DB00217 | approved | small molecule | Bethanidine | Therapeutic strategy associated | Details |
| R0087 | DB00226 | approved | small molecule | Guanadrel | Indication associated | Details |
| R0090 | DB00232 | withdrawn | small molecule | Methyclothiazide | Therapeutic strategy associated | Details |
| R0098 | DB00264 | approved; investigational | small molecule | Metoprolol | Therapeutic strategy associated | Details |
| R0111 | DB00310 | approved | small molecule | Chlorthalidone | Therapeutic strategy associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00363 | 35119232 | J Basic Clin Physiol Pharmacol | Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. | Details |
| A00529 | 35052872 | Biomedicines | Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. | Details |
| A00812 | 34959080 | J Neurol Sci | Association of chronic liver disease with cognition and brain volumes in two randomized controlled trial populations. | Details |
| A00945 | 34922644 | Lancet Diabetes Endocrinol | Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. | Details |
| A01125 | 34862599 | Br J Pharmacol | Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. | Details |
| A01133 | 34860208 | J Occup Environ Med | Determination of Cardiovascular Risk in 56,262 Spanish Construction Workers: Cardiovascular Risk in Construction Workers. | Details |
| A01463 | 34738990 | J Hypertens | Fatty liver index and hypertension-mediated organ damage in never-treated hypertensive patients without diabetes mellitus. | Details |
| A01718 | 34641807 | BMC Geriatr | A low follicle-stimulating hormone level is a protective factor for non-alcoholic fatty liver disease in older men aged over 80. | Details |
| A02015 | 34530527 | Clin Mol Hepatol | Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes. | Details |
| A02110 | 34503976 | Mol Pharmacol | Construction and Characterization of CRISPR/Cas9 Knockout Rat Model of Carboxylesterase 2a Gene. | Details |
| A02567 | 34326946 | World J Diabetes | Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. | Details |
| A02656 | 34295987 | Clin Exp Hepatol | Correlation of endoscopic findings with Doppler ultrasound in portal hypertension in children. | Details |
| A02744 | 34262716 | Food Sci Nutr | Effect of garlic powder supplementation on blood pressure and hs-C-reactive protein among nonalcoholic fatty liver disease patients: A randomized, double-blind, placebo-controlled trial. | Details |
| A02990 | 34171957 | Vnitr Lek | The use of moxonidine in the treatment of arterial hypertension. | Details |
| A03086 | 34136497 | Front Med (Lausanne) | Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. | Details |
| A03289 | 34059612 | Curr Opin Cardiol | Update on cardiovascular risk in nonalcoholic fatty liver disease. | Details |
| A03331 | 34041187 | J Family Med Prim Care | Number needed to screen to prevent progression of liver fibrosis to cirrhosis at primary health centers: An experience from Delhi. | Details |
| A03377 | 34025131 | J Ginseng Res | Effect of Korean Red Ginseng on metabolic syndrome. | Details |
| A04039 | 33780129 | Am J Transplant | Sleeve gastrectomy prior to liver transplantation is superior to medical weight loss in reducing posttransplant metabolic complications. | Details |
| A04490 | 33598084 | Pan Afr Med J | Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes. | Details |